ALNY Alnylam Inc. Company Total Asset Base

Official company branding of Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals (ALNY) maintains its leadership through patent control over RNA technologies, ensuring high profitability and protection against replication. Business stability relies on a monopoly position in the treatment of orphan diseases, guaranteeing a predictable cash flow. This chart of total asset values on GURU.Markets reflects a value of 6423.58. The company's impeccable authority within the biotech environment confirms its status as a creator of vital therapeutic solutions.

Alnylam Inc. - ALNY Company Total Assets (period 07/04/2022 - 10/31/2026)

Financial and market metric breakdowns for Alnylam Inc. (ALNY)

- stock value and consensus price forecast:
Market Price alnylam.com|ALNY - Price Target Chart
- market capitalization data:
Market Capitalization Alnylam Corp|ALNY - Total Company Value
- shareholders' equity book value data:
Share Book Value Alnylam|ALNY - Book Capitalization|Market-to-Book Ratio alnylam.com|ALNY - Company Total Assets
- debt and liquidity details:
Total Debt to Equity Ratio Alnylam Pharmaceuticals|ALNY - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Alnylam Corp|ALNY - Company Aggregate Debts|Debts to Book Capitalization Alnylam Corp|ALNY - Company Long-Term Debt|Company Short-Term Debt Alnylam|Interim Coverage Ratio alnylam.com
- financial results and valuation multiples details:
ALNY - Net Income
Fundamental valuation:Alnylam Pharmaceuticals
Core merchandise of Alnylam Pharmaceuticals

Total assets consolidate all company resources, determining its aggregate value through a reverse calculation of return on assets (ROA). The dynamics of this metric allow for the identification of hidden balance sheet distortions and an assessment of the issuer's actual financial stability. By analyzing the total assets figure, an investor can track capital purity without the risk of it being frozen. For Alnylam Pharmaceuticals (ALNY), this confirms the ability to develop RNA therapy independently, utilizing licensing alliances instead of acquisitions.

Main competitors

Company Assets vrtx.com (VRTX)|Aggregate Company Assets Insmed|United Therapeutics Corp (UTHR) - Company Total Asset Base|Aggregate Company Assets BioMarin Pharma (BMRN)|BBIO: Total Asset Value of Company|Company Total Assets BGM (BGM Group)|cogentbio.com (COGT) - Company Assets|Xeris Biopharma Holdings - Company Total Assets|Keros Therapeutics Inc (KROS) - Cumulative Company Assets|ARCT: Company Total Assets|ETON - Company Total Asset Base|KMDA (Kamada Ltd.) - Company Total Assets|Company Total Assets fulcrumtx.com|Aggregate Company Assets Abeona Therapeutics (ABEO)|Aggregate Company Assets MREO (mereobiopharma.com)|Company Total Assets PLX (Protalix)|Company Total Asset Base Pliant Therapeutics Inc (PLRX)|APLT: Cumulative Company Assets|Total Asset Value of Company RNTX|GELS: Company Total Assets|Company Assets Aytu BioPharma (AYTU)|CMMB (Chemomab Therapeutics Ltd) - Company Total Assets|Total Business Assets SRXH (SRx Health)|Cumulative Company Assets PLRZ (Polyrizon Ltd)|AEZS (zentaris.com) - Aggregate Asset Value|Aggregate Company Assets Cyclo Therapeutics, Inc. CYTH|INZY (Inozyme Pharma Inc.) - Total Asset Value of Company|Reneo Pharma - Company Total Assets|Aggregate Asset Value CSCI (COSCIENS Bio)